Your browser is no longer supported. Please, upgrade your browser.
DRNA Dicerna Pharmaceuticals, Inc. monthly Stock Chart
DRNA [NASD]
Dicerna Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.61 Insider Own0.10% Shs Outstand74.52M Perf Week7.54%
Market Cap1.75B Forward P/E- EPS next Y-1.03 Insider Trans-58.32% Shs Float68.75M Perf Month16.80%
Income-115.80M PEG- EPS next Q-0.05 Inst Own81.10% Short Float8.39% Perf Quarter39.83%
Sales130.40M P/S13.45 EPS this Y-10.20% Inst Trans-3.11% Short Ratio9.96 Perf Half Y18.04%
Book/sh2.06 P/B11.91 EPS next Y4.60% ROA-16.60% Target Price35.00 Perf Year2.10%
Cash/sh8.53 P/C2.88 EPS next 5Y- ROE-71.70% 52W Range11.75 - 27.68 Perf YTD11.39%
Dividend- P/FCF8.81 EPS past 5Y10.10% ROI-84.20% 52W High-11.34% Beta1.31
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin- 52W Low108.85% ATR1.13
Employees187 Current Ratio2.60 Sales Q/Q511.30% Oper. Margin-94.30% RSI (14)71.73 Volatility4.49% 5.27%
OptionableYes Debt/Eq0.00 EPS Q/Q34.90% Profit Margin-88.80% Rel Volume0.75 Prev Close23.37
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume579.17K Price24.54
Recom1.60 SMA209.02% SMA5019.00% SMA20018.79% Volume434,572 Change5.01%
Aug-07-20Reiterated H.C. Wainwright Buy $32 → $35
May-13-20Initiated RBC Capital Mkts Outperform $35
Mar-19-20Initiated Berenberg Buy $35
Nov-19-19Reiterated H.C. Wainwright Buy $22 → $30
Oct-29-19Initiated Robert W. Baird Outperform
May-24-19Resumed Citigroup Buy $30
Jan-22-19Upgrade Chardan Capital Markets Neutral → Buy $18
Nov-06-18Upgrade B. Riley FBR Neutral → Buy $13.50 → $21
Sep-13-18Initiated Citigroup Buy $27
Aug-15-18Upgrade H.C. Wainwright Neutral → Buy $21
Aug-09-18Reiterated Stifel Buy $18 → $20
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $10
Mar-23-18Downgrade H.C. Wainwright Buy → Neutral $12
Mar-09-18Initiated Chardan Capital Markets Neutral
Feb-05-18Initiated SunTrust Buy $13
Jan-16-18Initiated Evercore ISI Outperform $14
Nov-03-17Reiterated H.C. Wainwright Buy $6 → $10
May-23-17Resumed H.C. Wainwright Buy $5
Apr-10-17Reiterated H.C. Wainwright Buy $8 → $5
Jan-31-17Resumed Leerink Partners Mkt Perform
Nov-16-20 07:31AM  
07:30AM  
Nov-11-20 04:05PM  
Nov-10-20 04:05PM  
Nov-09-20 02:42PM  
Nov-07-20 08:54AM  
Nov-06-20 02:30PM  
Nov-05-20 04:05PM  
02:30PM  
Nov-02-20 04:30PM  
Nov-01-20 12:00PM  
Oct-29-20 04:05PM  
12:34PM  
Oct-26-20 11:54PM  
Oct-22-20 10:05AM  
Oct-15-20 04:12PM  
Oct-13-20 04:05PM  
07:00AM  
Oct-09-20 04:05PM  
Oct-01-20 04:30PM  
Sep-28-20 04:05PM  
Sep-16-20 04:24PM  
07:30AM  
Sep-10-20 04:17PM  
Sep-02-20 04:05PM  
Sep-01-20 04:30PM  
Aug-06-20 08:35AM  
07:01AM  
07:00AM  
Aug-05-20 04:05PM  
Aug-03-20 04:30PM  
Jul-30-20 12:33PM  
Jul-24-20 07:30AM  
Jul-21-20 08:11AM  
Jul-20-20 11:06AM  
Jul-01-20 04:30PM  
Jun-18-20 07:30AM  
Jun-15-20 08:49AM  
Jun-12-20 08:31AM  
Jun-08-20 03:24AM  
Jun-05-20 09:40AM  
Jun-01-20 04:30PM  
May-26-20 04:05PM  
May-18-20 06:29AM  
May-12-20 04:05PM  
May-10-20 10:39PM  
09:23AM  
May-09-20 04:31PM  
May-08-20 07:59AM  
May-07-20 06:45PM  
04:05PM  
04:01PM  
02:59PM  
May-01-20 04:30PM  
Apr-30-20 04:05PM  
Apr-29-20 07:36AM  
Apr-08-20 06:00AM  
Apr-06-20 06:26PM  
10:30AM  
07:00AM  
Apr-01-20 04:30PM  
Mar-31-20 07:30AM  
Mar-26-20 04:05PM  
Mar-23-20 06:23PM  
Mar-19-20 07:37AM  
Mar-18-20 04:05PM  
Mar-09-20 01:25PM  
Mar-02-20 04:30PM  
Feb-29-20 08:53AM  
Feb-27-20 06:25PM  
04:05PM  
Feb-20-20 04:05PM  
Feb-18-20 04:05PM  
Feb-10-20 07:30AM  
Feb-03-20 04:30PM  
Jan-29-20 12:45PM  
Jan-17-20 05:40PM  
Jan-02-20 04:30PM  
08:10AM  
07:30AM  
Jan-01-20 07:40AM  
Dec-19-19 07:30AM  
Dec-18-19 11:03AM  
Dec-17-19 04:12PM  
07:30AM  
06:00AM  
Dec-16-19 08:00AM  
Dec-15-19 08:46AM  
Dec-08-19 03:46PM  
Dec-03-19 08:29AM  
Dec-02-19 04:30PM  
Nov-26-19 04:05PM  
Nov-25-19 04:21PM  
Nov-19-19 07:56AM  
Nov-18-19 06:00AM  
Nov-15-19 12:30PM  
Nov-13-19 04:05PM  
Nov-07-19 04:05PM  
Nov-04-19 07:30AM  
Nov-01-19 08:06PM  
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paglia Regina M.Chief Human Resources OfficerNov 04Option Exercise12.9330,000387,90030,000Nov 06 05:58 PM
Paglia Regina M.Chief Human Resources OfficerNov 04Sale22.7530,000682,5000Nov 06 05:58 PM
Weissman James BChief Operating Officer & EVPNov 02Option Exercise3.424,36014,91136,220Nov 03 08:19 PM
Brown Bob DSee RemarksNov 02Option Exercise3.428,18527,99334,702Nov 03 08:23 PM
Brown Bob DSee RemarksNov 02Sale21.038,185172,13126,517Nov 03 08:23 PM
Weissman James BChief Operating Officer & EVPNov 02Sale20.954,36091,33331,860Nov 03 08:19 PM
Weissman James BChief Operating Officer & EVPOct 20Option Exercise2.9710,00029,70031,860Oct 22 08:45 PM
Brown Bob DSee RemarksOct 16Option Exercise3.4216,37055,98542,887Oct 20 07:32 PM
Brown Bob DSee RemarksOct 16Sale21.0016,370343,77026,517Oct 20 07:32 PM
Weissman James BChief Operating Officer & EVPOct 15Option Exercise3.428,72029,82230,580Oct 19 09:59 PM
Weissman James BChief Operating Officer & EVPOct 15Sale20.208,720176,14421,860Oct 19 09:59 PM
Brown Bob DSee RemarksSep 16Option Exercise3.4221,25072,67526,517Sep 18 08:03 PM
Brown Bob DSee RemarksSep 14Option Exercise3.422679135,267Sep 16 08:01 PM
FAMBROUGH DOUGLASPresident and CEOSep 01Buy18.0610,000180,59722,300Sep 01 08:33 PM
Brown Bob DSee RemarksAug 03Option Exercise3.428,18527,99313,185Aug 05 07:00 PM
Weissman James BEVP & Chief Operating OfficerAug 03Option Exercise3.004,36013,06626,220Aug 05 07:01 PM
Brown Bob DSee RemarksAug 03Sale22.488,185183,9875,000Aug 05 07:00 PM
Weissman James BEVP & Chief Operating OfficerAug 03Sale22.474,36097,97821,860Aug 05 07:01 PM
Brown Bob DSee RemarksJul 01Option Exercise3.428,18527,99313,185Jul 06 09:01 PM
Weissman James BChief Operating Officer & EVPJul 01Option Exercise2.974,36012,94926,220Jul 06 09:00 PM
Brown Bob DSee RemarksJul 01Sale26.508,185216,9295,000Jul 06 09:01 PM
Weissman James BChief Operating Officer & EVPJul 01Sale26.534,360115,67921,860Jul 06 09:00 PM
Brown Bob DSee RemarksJun 19Option Exercise2.979,67028,72014,670Jun 23 08:01 PM
Brown Bob DSee RemarksJun 19Sale25.009,670241,7505,000Jun 23 08:01 PM
Brown Bob DSee RemarksJun 01Option Exercise3.428,18527,99313,185Jun 02 08:00 PM
Weissman James BChief Operating Officer & EVPJun 01Option Exercise2.974,36012,94926,220Jun 02 08:02 PM
Weissman James BChief Operating Officer & EVPJun 01Sale21.064,36091,80721,860Jun 02 08:02 PM
Brown Bob DSee RemarksJun 01Sale21.018,185171,9595,000Jun 02 08:00 PM
Brown Bob DSee RemarksMay 11Option Exercise2.9713,28139,44518,281May 12 08:00 PM
Brown Bob DSee RemarksMay 11Sale24.0013,281318,7445,000May 12 08:00 PM
Brown Bob DSee RemarksMay 05Option Exercise3.428,18527,99313,185May 07 08:01 PM
Brown Bob DSee RemarksMay 05Sale21.008,185171,8855,000May 07 08:01 PM
Weissman James BChief Operating Officer & EVPMay 04Option Exercise2.974,36012,94926,220May 06 08:00 PM
Weissman James BChief Operating Officer & EVPMay 04Sale20.204,36088,07221,860May 06 08:00 PM
Brown Bob DSee RemarksApr 20Option Exercise2.9713,28139,44518,281Apr 21 08:01 PM
GREEN JOHN BChief Financial OfficerApr 20Option Exercise5.4525,624139,65145,045Apr 22 08:00 PM
GREEN JOHN BChief Financial OfficerApr 20Sale22.9525,624588,07119,421Apr 22 08:00 PM
Brown Bob DSee RemarksApr 20Sale23.0013,281305,4635,000Apr 21 08:01 PM
Brown Bob DSee RemarksApr 17Option Exercise3.428,18527,99313,185Apr 21 08:01 PM
Brown Bob DSee RemarksApr 17Sale21.188,185173,3585,000Apr 21 08:01 PM
Weissman James BChief Operating Officer & EVPApr 13Option Exercise2.974,36012,94926,220Apr 14 08:33 PM
Weissman James BChief Operating Officer & EVPApr 13Sale20.204,36088,07221,860Apr 14 08:33 PM
GREEN JOHN BChief Financial OfficerApr 07Option Exercise3.8820,46979,39539,890Apr 09 08:13 PM
GREEN JOHN BChief Financial OfficerApr 07Sale19.9520,469408,35719,421Apr 09 08:13 PM
Brown Bob DSee RemarksMar 02Option Exercise3.428,18527,99313,185Mar 03 08:31 PM
Weissman James BEVP & Chief Operating OfficerMar 02Option Exercise2.974,36012,94926,220Mar 03 08:30 PM
Brown Bob DSee RemarksMar 02Sale21.008,185171,8855,000Mar 03 08:31 PM
Weissman James BEVP & Chief Operating OfficerMar 02Sale20.614,36089,85421,860Mar 03 08:30 PM
Brown Bob DSee RemarksFeb 10Option Exercise3.428,18527,99313,185Feb 11 08:01 PM
Brown Bob DSee RemarksFeb 10Sale21.008,185171,8855,000Feb 11 08:01 PM
Weissman James BEVP & Chief Operating OfficerFeb 03Option Exercise2.974,36012,94926,220Feb 04 08:03 PM
Weissman James BEVP & Chief Operating OfficerFeb 03Sale20.204,36088,07221,860Feb 04 08:03 PM
GREEN JOHN BChief Financial OfficerJan 17Option Exercise2.9747,969142,46867,390Jan 21 08:00 PM
GREEN JOHN BChief Financial OfficerJan 17Sale21.2747,9691,020,16419,421Jan 21 08:00 PM
Weissman James BEVP & Chief Operating OfficerJan 02Option Exercise3.124,36013,62426,220Jan 03 08:00 PM
Weissman James BEVP & Chief Operating OfficerJan 02Sale21.884,36095,37621,860Jan 03 08:00 PM
Brown Bob DSee RemarksDec 31Option Exercise3.1016,94152,56516,941Dec 31 07:00 PM
Brown Bob DSee RemarksDec 31Sale22.0011,941262,7025,000Dec 31 07:00 PM
Brown Bob DSee RemarksDec 30Option Exercise3.2513,13642,69722,806Dec 31 07:00 PM
Brown Bob DSee RemarksDec 30Sale21.8522,806498,4010Dec 31 07:00 PM
ROSSKAMP RALFChief Medical OfficerDec 26Option Exercise2.9120,00058,20023,564Dec 27 08:08 PM
ROSSKAMP RALFChief Medical OfficerDec 26Sale22.6920,000453,7643,564Dec 27 08:08 PM
Weissman James BEVP & Chief Operating OfficerDec 18Option Exercise9.0911,00199,99925,705Dec 19 08:34 PM
FAMBROUGH DOUGLASChief Executive OfficerDec 18Option Exercise3.4280,000273,60092,300Dec 19 08:54 PM
FAMBROUGH DOUGLASChief Executive OfficerDec 18Sale25.8780,0002,069,58612,300Dec 19 08:54 PM
FAMBROUGH DOUGLASChief Executive OfficerDec 17Sale26.1759,0211,544,34512,300Dec 19 08:54 PM
GREEN JOHN BChief Financial OfficerDec 11Option Exercise5.458,00043,60018,698Dec 11 08:00 PM
Koppel AdamDirectorDec 04Sale24.681,500,00037,020,0004,080,237Dec 06 05:00 PM
Weissman James BEVP & Chief Operating OfficerDec 02Option Exercise2.9720,00059,40034,704Dec 03 08:00 PM
Weissman James BEVP & Chief Operating OfficerDec 02Sale26.0020,000520,00014,704Dec 03 08:00 PM
Kolchinsky PeterDirectorDec 02Sale24.98137,1763,427,1370Dec 02 04:30 PM
Kolchinsky PeterDirectorNov 29Sale24.22138,0003,341,725137,176Dec 02 04:30 PM